- Open Access
The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3β pathway and β-catenin stability
© Benelli et al; licensee BioMed Central Ltd. 2010
Received: 21 December 2009
Accepted: 10 June 2010
Published: 10 June 2010
Prostate cancer shows an extremely slow progression, appearing in its metastatic, hormone refractory phenotype mostly in elderly men. The chemopreventive targeting of this tumor could accordingly delay its malignancy over life expectancy. The cancer chemopreventive retinoid N-(4 hydroxyphenyl)retinamide (4HPR) has already been shown to restrain prostate cancer growth in vitro and in vivo, though its mechanisms of action are only partially explained.
We found that 4HPR impairs DU145 and PC3 prostate cancer cells migration and invasion by down-regulating FAK and AKT activation and by enhancing β-catenin degradation, causing the downregulation of target genes like cyclin D1, survivin and VEGF. This non-migratory phenotype was similarly produced in both cell lines by stable silencing of β-catenin. 4HPR was able to decrease AKT phosphorylation also when powerfully upregulated by IGF-1 and, consequently, to impair IGF-1-stimulated cell motility. Conversely, the expression of constitutively active AKT (myr-AKT) overcame the effects of 4HPR and β-catenin-silencing on cell migration. In addition, we found that BMP-2, a 4HPR target with antiangiogenic activity, decreased prostate cancer cell proliferation, migration and invasion by down-regulating the pathway described involving AKT phosphorylation, β-catenin stability and cyclin D1 expression.
These data point to 4HPR as a negative regulator of AKT phosphorylation, effectively targeting the β-catenin pathway and inducing a relatively benign phenotype in prostate cancer cells, limiting neoangiogenesis and cell invasion.
Prostate cancer (PC) is the most frequent cancer in men of western countries. About 1 man in 5 is diagnosed with PC during his lifetime and 1 man in 33 will die of this disease. As the population age is increasing, these numbers are expected to increase. PC cells usually remain confined in the organ, while a small proportion of carcinomas acquire the ability to metastasize and approximately 80% of patients who have died of advanced hormone refractory PC have clinical evidence of bone metastasis. Early stage disease differs from later stages in tumor volume, localization and metastatic potential. Processes involved in later stage disease, like development of androgen independence as a consequence of androgen depletion therapy, neoangiogenesis and homing of metastatic cells in lymphatic or bone tissues are generally undetectable at early stages. Among control strategies, chemoprevention attempts in preclinical studies to halt or delay these processes are now proving the potential efficacy of this approach.
4HPR, also known as fenretinide, has received great attention as a chemopreventive agent based on the cumulative results of numerous in vitro and animal studies, as well as chemoprevention clinical trials . 4HPR administration prevents prostate tumor growth and metastasis in animals [2–6] and functions as an apoptosis inducer in human prostate cancer cells in vitro [7–9] mostly through the production of reactive oxygen species (ROS) and mitochondrial disruption . Interestingly, 4HPR was shown to lower circulating insulin-like growth factor I (IGF-I) levels which have been associated with a higher risk of prostate cancer in several cohort studies [10, 11].
We and others have previously reported that the chemopreventive effects of 4HPR in early intervention protocols are likely due to its antiangiogenic properties [4, 12–16]. Since angiogenesis and metastatic spread are strictly related, in this study we analyzed the regulation of multiple signaling pathways responsible for cancer cell invasion. We found that 4HPR-induced inhibition of PC cell migration and invasion correlates with decreased FAK and AKT phosphorylation, activation of the glycogen synthase kinase 3β(GSK3β) and β-catenin destabilization. As a consequence, 4HPR led to the regulation of genes controlling cell proliferation, angiogenesis and metastasis. For the slow evolving prostate tumor to become metastatic multiple mechanisms must be activated and our results identify novel points of regulation by 4HPR, independent of ROS generation, that further support its use as a chemopreventive or therapeutic agent. Due to its pleiotropic activities, 4HPR could be used alone, with other chemopreventive molecules exhibiting complementary mechanisms of action, or in combination with chemotherapy to treat prostate cancer.
Cell culture and reagents
Androgen-independent DU145 and PC3 prostate carcinoma cell lines (ATCC, Rockville, MD) were cultured in RPMI containing 10% heat-inactivated FCS. DU145 subclones resistant to 5 μM 4HPR (R5) were established from cultures progressively exposed to increasing concentrations of 4HPR starting from 1 μM and cloning by limiting dilution following published procedures . 4HPR (kindly provided by Dr. James A. Crowell, Division of Cancer Prevention, NCI, Bethesda and Dr. Gregg Bullard, McKessonBio, Rockville, MD) was dissolved in ethanol at a stock concentration of 10 mM and stored in aliquots at -20°. Wortmannin, LY294002, N-Acetyl-L-cysteine (NAC) and diphenyleneiodionium chloride (DPI) were from Sigma (Milano, Italy), IGF-1 and bone morphogenetic protein-2 (BMP-2) were from R&D (Minneapolis, MN, USA). VEGF protein released into the media by PC cells was measured using a commercial human ELISA kit (Biosource, Invitrogen, Carlsbad, CA, USA).
Cell proliferation, apoptosis, chemotaxis and invasion assays
In vitro cell proliferation was performed on cells plated in 96-well plates at 3,000 cells/well dilution and grown in complete medium or treated as described. The medium was changed every two days. At different time points, the number of viable cells was evaluated by the crystal violet assay.
Chemotaxis and chemoinvasion assays were carried out in Boyden chambers as previously described . The cells (12 × 104/chamber) were extensively washed with PBS, resuspended in serum-free media (SFM) and placed in the upper compartment with or without selected molecules. In parallel experiments, trypan blue exclusion under all the conditions tested showed no altered cell proliferation or viability compared with controls during the five hours of chemotaxis test. The two compartments of the Boyden chamber were separated by 8 μm pore-size polycarbonate filters coated with 5 μg/50 μl/filter of collagen type IV (diluted in H2O, 0.1% CH3COOH) for the chemotaxis assay, or with Matrigel (60 μg/filter), a reconstituted basement membrane, for the invasion assay. Serum free 24 h-conditioned medium from human fibroblasts (FB-CM) was used as a chemoattractant in the lower chamber. After 5 hours of incubation at 37° in 5% CO2, the filters were recovered, fixed in ETOH and stained by Toluidine blue after removal of the non-migrating cells on the upper surface. The migrated cells were quantified counting five to ten fields for each filter under a microscope. Graphical results are shown as percent inhibition as compared to a 100% untreated control.
Protein extraction and western blot analyses
Proteins were obtained from PC cells after four hours culture in the absence or presence of the indicated molecules as described in the text and in figure legends, or after 4 days in the presence of BMP-2 (50-100 ng/ml). To perform AKT activation, thirty min before the end of the incubation, the cells were stimulated with IGF-I (100 ng/ml). The cells were then lysed in RIPA buffer containing protease inhibitors. Protein concentration was determined with the DC Protein Assay kit (Bio-Rad). Equal amounts of samples were resolved by SDS-PAGE, transferred to nitrocellulose and probed at 4°C overnight with the following anti-human antibodies (Cell Signaling Technology, Beverly, MA): rabbit polyclonal anti-phospho-FAK (Tyr576/577), phospho-AKT-1 (Ser473), phospho-GSK3β (Ser9), β-catenin, phospho-β-catenin (Ser552), cyclin D1, survivin and E-cadherin. After washing, the blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies (GE-Healthcare, Milano, Italy) and specific complexes were revealed by enhanced chemiluminescence (ECL, GE-Healthcare). An anti-GAPDH antibody conjugated to horseradish peroxidase (Novus Biologicals, Littleton, CO) or a mouse monoclonal anti-β-tubulin antibody (Sigma, Milano, Italy) were utilized as loading controls for all samples.
Plasmid DNA, RNA silencing and transfections
pCMV6-Myr.Akt (a constitutively active Akt) and control vector were kindly provided by Dr. Alex Toker of the Beth Israel Deaconess Medical Center of Boston. Transient transfections were performed with lipofectamine 2000 (Invitrogen). β-catenin was silenced using a lentiviral vector expressing short hairpin RNA (MISSION shRNA clones, Sigma) following manufacturer's instructions. This resulted in the generation of stable DU145 and PC3 cells showing decreased β-catenin expression. Control vectors contained scrambled sequences.
Data are expressed as means ± SD. The statistical significance between two data sets was determined by two-tailed unpaired Student's t test using the PRISM GraphPad software.
4HPR decreases cell proliferation, migration and invasion
Migration of cancer cells is one of the key factors responsible for cancer metastasis. To metastasize, cancer cells must migrate from the original growth site, invade surrounding tissues and locate to other parts of the body through the blood or the lymphatic system. The effects of 4HPR on PC cell migration and invasion were then tested in a broad dose/response experiment. Untreated PC cells migrated (Fig. 1A, B middle; DU145 and PC3 respectively) and invaded through Matrigel (Fig. 1A, B right; DU145 and PC3 respectively) in response to fibroblast conditioned medium (FB-CM). A very short exposure (5 h) to micromolar concentrations of 4HPR significantly inhibited migration and invasion of DU145 (Fig. 1A) and PC3 (Fig. 1B) cells. To explore the possibility that ROS induction by 4HPR was a mechanism underlying these effects, PC3 cells were pretreated 1 h with the ROS scavengers NAC and DPI (at 10 mM and 1 μM respectively) and then subjected to chemotaxis in the presence of 4HPR at different concentrations. As shown in Fig. 1C, both compounds did not modify 4HPR effects. Additional Fig. 1 (Fig. 1S) shows that 30 min pretreatment with the ROS scavenger N-Acetyl Cysteine (NAC) at 10 mM significantly decreases ROS production induced by 4HPR treatment (1 h at 5 μM).
4HPR modulates biological responses involved in the metastatic process of prostate cancer
Next, we determined the effect of overexpression of myristoylated Akt (Myr.Akt), which is anchored to the plasma membrane and has a constitutively active kinase activity. Cells transfected with the empty vector were used as controls. Western blot analysis of extracts from DU145 cells transiently transfected with constitutively active Akt showed high levels of total Akt and phosphorylated (Ser 473)-Akt as compared with the empty vector-transfected control cells (Fig. 3C). Ectopic expression of constitutively active Akt abrogated 4HPR-mediated inhibition of DU145 cell migration (Fig. 3C).
The oncogenic hub β-catenin is a molecular target of 4HPR
The expression of β-catenin is rather low in non-cancer cells as GSK-3β causes its phosphorylation and consequent degradation by the ubiquitin-proteasome pathway. GSK-3β activity is suppressed when it is phosphorylated on serine 9 by AKT. In agreement with the decreased phosphorylation of AKT after 4HPR treatment (Fig. 2A, B, 3B), GSK-3β phosphorylation was decreased by 4HPR (Fig. 4A, left). As a confirmation, a short exposure (2 hrs) to the specific PI3K/AKT inhibitors Wortmannin and LY294002 reduced GSK3β phosphorylation,β-catenin and cyclin D1 levels (Fig. 4B). AKT was also shown to directly phosphorylate β-catenin at Ser552, independent of GSK3β. Phosphorylation at Ser552 induces β-catenin accumulation in the nucleus, increases its transcriptional activity and promotes cell invasion [27, 28]. According to AKT inhibition by 4HPR exposure, β-catenin phosphorylated at Ser552, probably representing the residual nuclear pool escaping proteasomal degradation, was decreased (Fig. 4A, left). Activation of AKT by IGF-I exposure (Fig. 4C) suppressed GSK3β activity, stabilized β-catenin, increased Ser552 phosphorylation and cyclin D1 levels, yet pretreatment with 4HPR abolished the effects of IGF-I stimulation (Fig. 4C). Together, all these data suggest that 4HPR-induced pAKT down-regulation exerts a multi-level control on total and nuclear β-catenin, dependent and independent of GSK3β activity.
In order to understand whether the observed signaling was univocally related to sensitivity of cell lines to 4HPR, our analysis was extended to DU145/R5, a cell line resistant to 5 μM 4HPR generated by in vitro incubation of DU145 cells with increasing concentrations of 4HPR. Supplementary Fig. 2 (Fig. 2S) shows that DU145/R5 cells grow (96 h treatment, panel A) and migrate (5 h treatment, panel B) in the presence of 2.5 and 5 μM 4HPR. This 4HPR-resistant phenotype is associated to very high levels of phosphorylated AKT (panel C).
Effect of β-catenin silencing in human prostate cancer DU145 and PC3 cells
Next, we determined whether constitutively active Akt (Myr.Akt) could abrogate the effects of β-catenin silencing on cell migration and invasion. β-catenin-silenced DU145 cells transiently expressing Myr.Akt showed an enhanced migratory and invasive phenotype as compared to control vector transfected cells (Fig. 5D). In these cells GSK3β phosphorylation and β-catenin levels remained unaltered (Fig. 5D, right panel), as previously reported , suggesting that under these conditions activation of Akt alone is not able to restore β-catenin levels through increased expression or stabilization.
4HPR-induced BMP2 in an anti-angiogenic setting antagonizes prostate cancer cell growth and invasiveness
E-cadherin enforces cell-cell contacts forming the adherens junctions and is anchored to actin filaments by β and α catenin. E-cadherin loss promotes metastasis by enabling the first step of the metastatic cascade: the disaggregation of cancer cells from each another. BMP-7, another member of the BMP family, has been reported to be a potent inhibitor of prostate cancer metastasis  also acting through E-cadherin induction. PC3 cells exposed to BMP-2 exhibited increased levels of E-cadherin (Fig. 6D) suggesting that BMP-7 and BMP-2 have similar mechanisms of action. We cannot exclude, however, that β-catenin downregulation controls E-cadherin expression as reported for other compounds .
Prostate cancer is the most frequently diagnosed cancer in men and a leading cause of cancer death. Although the 5-year survival rate is excellent for localized stages, the survival dramatically decreases when prostate cancer metastasizes. Decades of research have revealed that cancer is easier to prevent than to treat and for individuals at a high risk of developing cancer and/or for slow evolving cancers, such as prostate cancer, chemoprevention is a logical approach. Preneoplastic lesions such as high-grade prostatic intraepithelial neoplasia (PIN) are frequently observed in asymptomatic young men and it is believed that such lesions require two to three decades to develop into clinically relevant prostate cancer. The fact that prostate cancer is associated with advanced age again suggests that chemopreventive agents inhibiting or delaying the onset of malignancy might be recommended. Identification of molecular targets and signaling pathways of chemoprevention are therefore relevant to cancer therapy.
Several studies have reported a remarkable preventive activity of 4HPR in animal models of prostate cancer [2–6], but pilot clinical trials gave less encouraging results. One possible explanation for the contrasting results may be related to the low dose used in humans compared to those that were effective in animal studies or to the low bioavailability of 4HPR at the prostate tissue level as documented in biopsies . The elucidation of molecular pathways activated by 4HPR are fundamental clues to understand how this agent might be better used in a prevention setting and current trials are underway to re-examine both dose and schedule of 4HPR administration as well as the target tissues of interest.
Our study was designed to investigate the early effects of 4HPR on activated pathways, and regulated gene products, that control prostate cancer cell migration, invasion and proliferation later on. We found that 4HPR inhibited phosphorylated FAK, a protein tyrosine kinase localized at the cell membrane that signals through the PI3K/AKT pathway. Increasing levels of FAK in human prostate cancer correlate with greater metastatic potential . FAK overexpression appeared in PIN lesions, with a clear distribution of high staining in neoplastic cells, while normal cells in the surrounding tissue did not show elevated expression . Furthermore, benign prostate hyperplasia did not show a change in FAK expression compared to normal tissue . These observations support a role for FAK in the pre-metastasis phenotype. We provide evidence that the FAK-mediated decrease of AKT activity by 4HPR treatment, as well as AKT inactivation/activation with Wortmannin or LY294002 and IGF-I or Myr.Akt, respectively, tightly controls the chemotactic and metastatic phenotype of androgen-independent prostate carcinoma cells and may also explain the already described suppression of constitutive NF-k B activation, mediating invasion and osteoclastogenesis, in human prostate cancer cells exposed to 4HPR [12, 37]. Moreover, as both FAK and AKT signaling controls prostate tumor angiogenesis by up-regulating vascular endothelial growth factor [22, 38], our results showing reduction of VEGF release by 4HPR could be associated with FAK and AKT decreased activity.
The Wnt signaling pathway and its key component β-catenin play critical roles in embryonic development as well as in human diseases, including various malignancies. Accumulated evidence has demonstrated a significant role for the Wnt pathway in the development and progression of human prostate cancer. In the absence of a Wnt signal, β-catenin is constitutively down-regulated by a multicomponent phosphorylation destruction complex containing active GSK3β and targeted for degradation by the ubiquitin proteasome pathway. Stimulation of the Wnt pathway results in increased levels of nuclear β-catenin, which activates target genes (i.e cyclinD1) promoting G1-S transition and cell cycling. High levels of Wnt and β-catenin are associated with advanced, metastatic, hormone-refractory prostate carcinoma . Blockade of β-catenin signaling by chemopreventive agents suppresses prostate carcinogenesis and metastasis in TRAMP mice and decreased proliferation and invasiveness in DU145 cells, similar to that obtained with siRNA directed against β-catenin . Our data show that both DU145 and PC3 cell lines have high basal levels of soluble β-catenin indicative of an active Wnt signaling. We cannot exclude that 4HPR treatment, besides decreasing AKT phosphorylation, leads to β-catenin degradation by affecting other pathways inducing GSK3β phosphorylation such as Wnt- and ERK-mediated signaling.
Retinoids and the synthetic derivative 4HPR regulate gene expression through the RAR/RXR nuclear receptor family (NR). Retinoid-activated RAR and RXR are potent repressors of β-catenin signaling in retinoid-sensitive cells [39–41] and retinoid-mediated repression of several Wnt genes has been implicated as a required step in the differentiation of neuronal cells . These mechanisms may further contribute to the effectiveness of 4HPR as a chemopreventive agent in cancers with hyperactive Wnt signaling. Moreover, as β-catenin has the ability to enhance androgen receptor (AR) function in prostate cancer , the obvious therapeutic goal to abrogate potential oncogenic AR/β-catenin interactions can be easily achieved through the chemopreventive properties of 4HPR also in hormone responsive cells.
Prostate cancer has the ability to produce angiogenic factors and several studies showed that an increased microvessel density is associated with poorer prognosis. We and others [4, 12–16, 44, 45] have previously demonstrated that one possible mechanism of the chemopreventive activity of 4HPR is through inhibition of angiogenesis and invasion, in part mediated by BMP-2 production . In long-term experiments, prostate cancer cells exposed to BMP-2 concentrations attainable in vitro (50-100 ng/ml) from endothelial cells exposed to 5 μM 4HPR, showed a slight but significant decreased proliferation and reduced chemotactic and invasive activities. These effects again associate with decreased AKT activity and lower levels of β-catenin and cyclin D1, indicative of an interference with the β-catenin pathway, as already described in intestinal tumorigenesis in mice and humans [30, 31]. Of note, BMP-2 treatment also induced E-cadherin expression, indicative of a less metastatic phenotype. The role of BMPs in the formation of prostate cancer metastasis to bone remains unknown as demonstrated by the great number of published contrasting results. BMP-2, 4, 6 and 7 have in fact been shown to both induce and prevent bone metastasis [32, 46–51]. These contrasting results may be generated by the different experimental approaches utilized, time of exposure and concentrations of BMPs employed. We indeed obtained enhanced migration and invasion only when the cells were exposed to BMP-2 during the 5 hours of the assay (data not shown).
A large number of evidences point into the same direction: FAK, and its downstream signaling molecules AKT and GSK-3β, β-catenin and its upstream and downstream signaling molecules Wnt and cyclin D1, respectively, are important players in both prostate tumor development and metastasis. Simultaneous manipulation by the chemopreventive 4HPR of a number of signaling pathways, both in cancer and endothelial cells, all involved in the processes of tumor progression and metastasis formation is likely to be more effective than manipulation of single target molecules. Investigation of Wnt signaling molecules and identification of synergisms between 4HPR and other candidate chemopreventive molecules with complementary mechanisms of action may support future assessment of this prototype cancer preventive retinoid as an anti metastatic drug.
This work was supported by grants from the Ministero della Salute, the Compagnia di San Paolo and the Regione Liguria. We acknowledge Dr.Monica Ciarlo for technical assistance.
- Hail N Jr, Kim HJ, Lotan R: Mechanisms of fenretinide-induced apoptosis. Apoptosis. 2006, 11: 1677-1694. 10.1007/s10495-006-9289-3View ArticlePubMedGoogle Scholar
- Takahashi N, Watanabe Y, Maitani Y, Yamauchi T, Higashiyama K, Ohba T: p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action. Int J Cancer. 2008, 122: 689-698. 10.1002/ijc.23154View ArticlePubMedGoogle Scholar
- Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M: Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis. 2000, 18: 429-438. 10.1023/A:1010905309570View ArticlePubMedGoogle Scholar
- Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 1993, 53: 224-226.PubMedGoogle Scholar
- Pollard M, Luckert PH, Sporn MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res. 1991, 51: 3610-3611.PubMedGoogle Scholar
- Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC: Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993, 53: 4461-4465.PubMedGoogle Scholar
- Hsieh TC, Ng C, Wu JM: The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Biochem Mol Biol Int. 1995, 37: 499-506.PubMedGoogle Scholar
- Igawa M, Tanabe T, Chodak GW, Rukstalis DB: N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate. 1994, 24: 299-305. 10.1002/pros.2990240605View ArticlePubMedGoogle Scholar
- Sun SY, Yue P, Lotan R: Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol. 1999, 55: 403-410.PubMedGoogle Scholar
- Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998, 279: 563-566. 10.1126/science.279.5350.563View ArticlePubMedGoogle Scholar
- Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000, 92: 1910-1917. 10.1093/jnci/92.23.1910View ArticlePubMedGoogle Scholar
- Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB: N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res. 2005, 65: 9555-9565. 10.1158/0008-5472.CAN-05-1585View ArticlePubMedGoogle Scholar
- Ferrari N, Morini M, Pfeffer U, Minghelli S, Noonan DM, Albini A: Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clin Cancer Res. 2003, 9: 6020-6029.PubMedGoogle Scholar
- Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM, Albini A: The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide. Clin Cancer Res. 2005, 11: 4610-4619. 10.1158/1078-0432.CCR-04-2210View ArticlePubMedGoogle Scholar
- Tosetti F, Vene R, Arena G, Morini M, Minghelli S, Noonan DM, Albini A: N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death. Mol Pharmacol. 2003, 63: 565-573. 10.1124/mol.63.3.565View ArticlePubMedGoogle Scholar
- Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, Montaldo PG, De Falco G, Caruso A, Vacca A, Ponzoni M: Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer. 2001, 94: 314-321. 10.1002/ijc.1441View ArticlePubMedGoogle Scholar
- Appierto V, Cavadini E, Pergolizzi R, Cleris L, Lotan R, Canevari S, Formelli F: b>Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer. 2001, 84: 1528-1534. 10.1054/bjoc.2001.1826PubMed CentralView ArticlePubMedGoogle Scholar
- Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47: 3239-3245.PubMedGoogle Scholar
- Sonoda Y, Watanabe S, Matsumoto Y, Aizu-Yokota E, Kasahara T: FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J Biol Chem. 1999, 274: 10566-10570. 10.1074/jbc.274.15.10566View ArticlePubMedGoogle Scholar
- van Nimwegen MJ, van de Water B: Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol. 2007, 73: 597-609. 10.1016/j.bcp.2006.08.011View ArticlePubMedGoogle Scholar
- Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S: Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer. 2007, 121: 1424-1432. 10.1002/ijc.22862View ArticlePubMedGoogle Scholar
- Fang J, Ding M, Yang L, Liu LZ, Jiang BH: PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007, 19: 2487-2497. 10.1016/j.cellsig.2007.07.025PubMed CentralView ArticlePubMedGoogle Scholar
- Sachdev D, Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007, 6: 1-12. 10.1158/1535-7163.MCT-06-0080View ArticlePubMedGoogle Scholar
- Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D, Rabbani SA: Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004, 101: 1345-1356. 10.1002/cncr.20518View ArticlePubMedGoogle Scholar
- Takahashi-Yanaga F, Sasaguri T: GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal. 2008, 20: 581-589. 10.1016/j.cellsig.2007.10.018View ArticlePubMedGoogle Scholar
- Ma H, Nguyen C, Lee KS, Kahn M: Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 2005, 24: 3619-3631. 10.1038/sj.onc.1208433View ArticlePubMedGoogle Scholar
- Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z: Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007, 282: 11221-11229. 10.1074/jbc.M611871200PubMed CentralView ArticlePubMedGoogle Scholar
- Lu Z, Ghosh S, Wang Z, Hunter T: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003, 4: 499-515. 10.1016/S1535-6108(03)00304-0View ArticlePubMedGoogle Scholar
- Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Larue L: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003, 63: 2172-2178.PubMedGoogle Scholar
- He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM: BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet. 2004, 36: 1117-1121. 10.1038/ng1430View ArticlePubMedGoogle Scholar
- Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, Clevers H: De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science. 2004, 303: 1684-1686. 10.1126/science.1093587View ArticlePubMedGoogle Scholar
- Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R: BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol. 2007, 171: 1047-1057. 10.2353/ajpath.2007.070168PubMed CentralView ArticlePubMedGoogle Scholar
- Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI, Gupta S: Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res. 2007, 67: 6925-6935. 10.1158/0008-5472.CAN-07-0717View ArticlePubMedGoogle Scholar
- Thaller C, Shalev M, Frolov A, Eichele G, Thompson TC, Williams RH, Dillioglugil O, Kadmon D: Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000, 18: 3804-3808.PubMedGoogle Scholar
- Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S: Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer. 1996, 68: 164-171. 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-WView ArticlePubMedGoogle Scholar
- Rovin JD, Frierson HF, Ledinh W, Parsons JT, Adams RB: Expression of focal adhesion kinase in normal and pathologic human prostate tissues. Prostate. 2002, 53: 124-132. 10.1002/pros.10114View ArticlePubMedGoogle Scholar
- Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N: Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog. 2002, 35: 127-137. 10.1002/mc.10084View ArticlePubMedGoogle Scholar
- Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG: Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene. 2006, 25: 5969-5984. 10.1038/sj.onc.1209588View ArticlePubMedGoogle Scholar
- Shah S, Hecht A, Pestell R, Byers SW: Trans-repression of beta-catenin activity by nuclear receptors. J Biol Chem. 2003, 278: 48137-48145. 10.1074/jbc.M307154200View ArticlePubMedGoogle Scholar
- Easwaran V, Pishvaian M, Salimuddin , Byers S: Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol. 1999, 9: 1415-1418. 10.1016/S0960-9822(00)80088-3View ArticlePubMedGoogle Scholar
- Xiao JH, Ghosn C, Hinchman C, Forbes C, Wang J, Snider N, Cordrey A, Zhao Y, Chandraratna RA: Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem. 2003, 278: 29954-29962. 10.1074/jbc.M304761200View ArticlePubMedGoogle Scholar
- Katoh M: Regulation of WNT signaling molecules by retinoic acid during neuronal differentiation in NT2 cells: threshold model of WNT action (review). Int J Mol Med. 2002, 10: 683-687.PubMedGoogle Scholar
- Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC: Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?. Endocr Rev. 2005, 26: 898-915. 10.1210/er.2003-0034View ArticlePubMedGoogle Scholar
- Golubkov V, Garcia A, Markland FS: Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005, 25: 249-253.PubMedGoogle Scholar
- Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galietta LJ, Piccardi F: The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. Clin Cancer Res. 2009, 15: 1199-1209. 10.1158/1078-0432.CCR-08-2477View ArticlePubMedGoogle Scholar
- Lai TH, Fong YC, Fu WM, Yang RS, Tang CH: Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate. 2008, 68: 1341-1353. 10.1002/pros.20799View ArticlePubMedGoogle Scholar
- Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET: Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 2008, 68: 5785-5794. 10.1158/0008-5472.CAN-07-6541PubMed CentralView ArticlePubMedGoogle Scholar
- Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR: Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone. 2006, 38: 154-166. 10.1016/j.bone.2005.07.015View ArticlePubMedGoogle Scholar
- Qiu T, Grizzle WE, Oelschlager DK, Shen X, Cao X: Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1. Embo J. 2007, 26: 346-357. 10.1038/sj.emboj.7601499PubMed CentralView ArticlePubMedGoogle Scholar
- Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M: Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 1997, 57: 5022-5027.PubMedGoogle Scholar
- Tomari K, Kumagai T, Shimizu T, Takeda K: Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells. Int J Mol Med. 2005, 15: 253-258.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.